Biogen and Eisai change agreements on Alzheimer's drug

An amendment to Biogen and Eisai’s partnership deal means the latter will start receiving royalties from Aduhelm sales next year. The companies have also decided to extend collaborations on a new Alzheimer’s treatment.
Photo: BRIAN SNYDER/REUTERS / X90051
Photo: BRIAN SNYDER/REUTERS / X90051
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Going forward, Biogen and Eisai won’t be splitting global profits of Alzheimer’s drug Aduhelm (aducanumab), which is marketed in the US under the brand name Aduhelm, the companies announce in separate press releases.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading